Fluosphera has successfully completed preclinical trials, demonstrating promising results in targeted drug delivery and efficacy in cancer models. The company is now preparing for clinical trials to further validate its technology and advance towards commercialization.
Organizations Involved
SOSV, XYZ Ventures, National Cancer Institute
Founders
Emily Chen, Michael Johnson
Company Description
Fluosphera is a biotechnology company specializing in developing innovative therapies for cancer treatment. Their proprietary technology leverages nanotechnology to deliver targeted drug delivery systems that enhance the efficacy of chemotherapy while minimizing side effects. By precisely targeting cancer cells, Fluosphera's approach aims to revolutionize cancer treatment and improve patient outcomes.